In a model of cardiorenal syndrome following AKI, blockade of IL-33 markedly attenuated myocardial hypertrophy and renal fibrosis, highlighting the therapeutic potential of targeting inter-organ communication pathways [57]. The gene discussed is IL33; the disease is renal fibrosis.